223 related articles for article (PubMed ID: 31255282)
1. Potential anti-neuroblastoma agents from Juniperus oblonga.
Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Rhodiola crenulata on growth and metabolism of NB-1691, an MYCN-amplified neuroblastoma cell line.
Wong KE; Mora MC; Sultana N; Moriarty KP; Arenas RB; Yadava N; Schneider SS; Tirabassi MV
Tumour Biol; 2018 Jun; 40(6):1010428318779515. PubMed ID: 29871587
[TBL] [Abstract][Full Text] [Related]
3. Deoxypodophyllotoxin isolated from Juniperus communis induces apoptosis in breast cancer cells.
Benzina S; Harquail J; Jean S; Beauregard AP; Colquhoun CD; Carroll M; Bos A; Gray CA; Robichaud GA
Anticancer Agents Med Chem; 2015; 15(1):79-88. PubMed ID: 24913660
[TBL] [Abstract][Full Text] [Related]
4. Anti-mycobacterial natural products from the Canadian medicinal plant Juniperus communis.
Carpenter CD; O'Neill T; Picot N; Johnson JA; Robichaud GA; Webster D; Gray CA
J Ethnopharmacol; 2012 Sep; 143(2):695-700. PubMed ID: 22877928
[TBL] [Abstract][Full Text] [Related]
5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the Lignan Content in Extracts from Linum, Callitris and Juniperus Species in Relation to Their In Vitro Antiproliferative Activities.
Doussot J; Mathieu V; Colas C; Molinié R; Corbin C; Montguillon J; Moreno Y Banuls L; Renouard S; Lamblin F; Dupré P; Maunit B; Kiss R; Hano C; Lainé E
Planta Med; 2017 Apr; 83(6):574-581. PubMed ID: 27776375
[TBL] [Abstract][Full Text] [Related]
7. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
8. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
9. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
10.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
11. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.
Chen B; Hua Z; Gong B; Tan X; Zhang S; Li Q; Chen Y; Zhang J; Li Z
Life Sci; 2020 Sep; 256():117820. PubMed ID: 32512012
[TBL] [Abstract][Full Text] [Related]
13. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
14.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
15. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
16. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
19. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
20. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
